NO2021033I1 - Selineksor eller et farmasøytisk akseptabelt salt derav - Google Patents

Selineksor eller et farmasøytisk akseptabelt salt derav

Info

Publication number
NO2021033I1
NO2021033I1 NO2021033C NO2021033C NO2021033I1 NO 2021033 I1 NO2021033 I1 NO 2021033I1 NO 2021033 C NO2021033 C NO 2021033C NO 2021033 C NO2021033 C NO 2021033C NO 2021033 I1 NO2021033 I1 NO 2021033I1
Authority
NO
Norway
Prior art keywords
selinexor
pharmaceutically acceptable
acceptable salt
salt
pharmaceutically
Prior art date
Application number
NO2021033C
Other languages
English (en)
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of NO2021033I1 publication Critical patent/NO2021033I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
NO2021033C 2011-07-29 2021-09-06 Selineksor eller et farmasøytisk akseptabelt salt derav NO2021033I1 (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161513432P 2011-07-29 2011-07-29
US201161513428P 2011-07-29 2011-07-29
US201261610178P 2012-03-13 2012-03-13
US201261653588P 2012-05-31 2012-05-31
US201261654651P 2012-06-01 2012-06-01
PCT/US2012/048319 WO2013019548A1 (en) 2011-07-29 2012-07-26 Hydrazide containing nuclear transport modulators and uses thereof

Publications (1)

Publication Number Publication Date
NO2021033I1 true NO2021033I1 (no) 2021-09-06

Family

ID=46634546

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2021033C NO2021033I1 (no) 2011-07-29 2021-09-06 Selineksor eller et farmasøytisk akseptabelt salt derav

Country Status (35)

Country Link
US (8) US9079865B2 (no)
EP (3) EP4234545A3 (no)
JP (3) JP6005740B2 (no)
KR (5) KR20210083380A (no)
CN (5) CN103874690B (no)
AR (1) AR087342A1 (no)
AU (5) AU2012290454B2 (no)
BR (1) BR112014001934B1 (no)
CA (1) CA2842362C (no)
CL (2) CL2014000225A1 (no)
CO (1) CO6960539A2 (no)
CY (1) CY1119783T1 (no)
DK (2) DK3333164T3 (no)
EA (1) EA201490407A1 (no)
ES (2) ES2655645T3 (no)
FR (1) FR21C1042I2 (no)
GE (1) GEP201706616B (no)
HK (2) HK1198477A1 (no)
HR (1) HRP20180014T1 (no)
HU (2) HUE036058T2 (no)
LT (2) LT2736887T (no)
LU (1) LUC00219I2 (no)
ME (1) ME02936B (no)
MX (1) MX349712B (no)
NL (1) NL301119I2 (no)
NO (1) NO2021033I1 (no)
PE (1) PE20141170A1 (no)
PL (2) PL3333164T3 (no)
PT (1) PT2736887T (no)
RS (1) RS56823B1 (no)
SI (1) SI2736887T1 (no)
TW (1) TWI574957B (no)
UA (1) UA115532C2 (no)
WO (1) WO2013019548A1 (no)
ZA (1) ZA201401223B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513230B2 (en) 2010-03-05 2013-08-20 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US9303000B2 (en) 2011-01-17 2016-04-05 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
PL3333164T3 (pl) 2011-07-29 2023-12-18 Karyopharm Therapeutics Inc. Modulatory transportu jądrowego zawierające ugrupowanie hydrazydu i ich zastosowania
EA201490406A1 (ru) 2011-07-29 2014-07-30 Кариофарм Терапевтикс, Инк. Модуляторы ядерного транспорта и их применение
EP2805713B1 (en) 2012-01-18 2018-10-10 Bioneer Corporation Magnetic nanoparticle-samirna complex and method for preparing same
EP3404027B1 (en) * 2012-05-09 2020-03-04 Biogen MA Inc. Nuclear transport modulators and uses thereof
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
WO2014144772A1 (en) * 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
CN110183422B (zh) * 2013-06-21 2023-07-14 卡尔约药物治疗公司 核转运调节剂及其用途
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
MX2016000020A (es) 2013-07-05 2016-08-18 Bioneer Corp Estructura de nanoparticula del tipo oligonucleotido mejorada que tiene alta eficiencia y metodo para preparar la misma.
CN105705639A (zh) 2013-07-05 2016-06-22 柏业公司 登革病毒相关的基因特异性siRNA、包含该siRNA的双链寡RNA分子、和包含它们的用于抑制登革病毒复制的组合物
KR20150006743A (ko) * 2013-07-09 2015-01-19 (주)바이오니아 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US9861615B2 (en) * 2013-11-28 2018-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of beta-thalassemias
EP3128008A4 (en) 2014-04-04 2018-03-28 Bioneer Corporation Novel double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases
DK3180331T3 (da) * 2014-08-15 2022-09-12 Karyopharm Therapeutics Inc Polymorfer af selinexor
US10709706B2 (en) 2015-12-31 2020-07-14 Karopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
WO2017118940A1 (en) * 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
EP3241830A1 (de) 2016-05-04 2017-11-08 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
EP3512515A1 (en) 2016-09-16 2019-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
WO2018129227A1 (en) 2017-01-05 2018-07-12 Watson Laboratories Inc. Novel crystalline forms of selinexor and process for their preparation
CN106831617A (zh) * 2017-01-17 2017-06-13 广州市闻皓生物科技有限公司 一种Selinexor中间体的合成工艺
CN106831731B (zh) * 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
WO2018191707A2 (en) * 2017-04-13 2018-10-18 Brown University Nucleocytoplasmic regulator of autophagy-associated transcription factors
WO2019232724A1 (en) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
CN108947982A (zh) * 2018-08-16 2018-12-07 刘璐 治疗非酒精性脂肪肝病的吡嗪衍生物、组合物和应用
WO2020092965A1 (en) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 as a biomarker for treatments using xpo1 inhibitors
CN111606890A (zh) 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 含丙烯酰基的核转运调节剂及其用途
BR112021016762A2 (pt) 2019-03-20 2021-10-19 Johnson Matthey Public Limited Company Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor
MA55808A (fr) 2019-05-01 2022-03-09 Karyopharm Therapeutics Inc Procédé de préparation d'inhibiteurs de xpo1 et intermédiaires destinés à être utilisés dans la préparation d'inhibiteurs de xpo1
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
WO2021163338A1 (en) 2020-02-11 2021-08-19 Karyopharm Therapeutics Inc. Xpo1 inhibitors for use in treating cancer
CN115485272A (zh) 2020-03-27 2022-12-16 朗多生物制药股份有限公司 Plxdc2配体
WO2021202745A1 (en) 2020-03-31 2021-10-07 Karyopharm Therapeutics Inc. Treatment of covid-19 with a sine compound
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2021252874A1 (en) 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Xpo1 inhibitors for use in treating cancer
WO2021252905A1 (en) 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Biomarkers for response to exportin-1 inhibitors in diffuse large b-cell lymphoma patients
WO2021252900A1 (en) 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Biomarkers for response to exportin-1 inhibitors in multiple myeloma patients
WO2022087218A1 (en) 2020-10-21 2022-04-28 Karyopharm Therapeutics Inc. Crystalline form of selinexor
CN112679477B (zh) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 塞利尼索及其中间体的制备方法
WO2022143779A1 (zh) * 2020-12-29 2022-07-07 南京明德新药研发有限公司 含烯基类化合物及其应用
WO2022232417A1 (en) 2021-04-28 2022-11-03 Karyopharm Therapeutics Inc. Biomarkers for response to exportin-1 inhibitors in multiple myeloma patients
WO2022246065A1 (en) 2021-05-19 2022-11-24 Karyopharm Therapeutics Inc. Calb1 biomarker in the treatment of de-differentiated liposarcoma using xpo1 inhibitors, such as selinexor
CN116514773A (zh) * 2023-04-24 2023-08-01 重庆汉佩生物科技有限公司 一种Verdinexor(KPT-335)及其盐酸盐的合成方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
JPS5661360A (en) * 1979-10-25 1981-05-26 Teijin Ltd 1-substituted imidazole derivative and its preparation
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
IL97249A (en) * 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
JP2941950B2 (ja) 1994-11-23 1999-08-30 ニューロゲン コーポレイション 或る種の４−アミノメチル−２−置換イミダゾール誘導体および２−アミノメチル−４−置換イミダゾール誘導体；新規な種類のドーパミン リセプタ亜型特異性リガンド
US20030018025A1 (en) * 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
CA2229617A1 (en) 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation
ATE341554T1 (de) 1996-04-04 2006-10-15 Shionogi & Co Cephemverbindungen und medikamente die diese verbindungen enthalten
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
ATE244219T1 (de) 1996-04-25 2003-07-15 Nissan Chemical Ind Ltd Ethylenderivate und pestizide
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
AU2960599A (en) 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
DE60138658D1 (de) 2000-09-29 2009-06-18 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine Amidgruppe zur Behandlung von Malaria
KR20040048411A (ko) 2001-09-14 2004-06-09 메틸진, 인크. 히스톤 데아세틸라아제의 억제제
WO2004037248A2 (en) 2002-10-24 2004-05-06 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
AR041867A1 (es) * 2002-11-01 2005-06-01 Takeda Pharmaceutical Agente para prevenir o tratar neuropatia
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
CA2504941C (en) 2002-11-08 2012-06-26 Neurogen Corporation 3-substituted-6-aryl pyridines
CA2512886A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
MY149038A (en) 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
EP1780210A4 (en) 2004-08-11 2009-06-10 Kyorin Seiyaku Kk NEW CYCLIC AMINOBENOIC ACID DERIVATIVE
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
US20100130737A1 (en) 2005-02-18 2010-05-27 Takeda Pharmaceutical Company Limited Regulating Agent of GPR34 Receptor Function
USRE46792E1 (en) 2005-11-15 2018-04-17 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
CA2643796A1 (en) 2006-03-09 2007-09-13 Eisai R & D Management Co., Ltd. Polycyclic cinnamide derivatives
ES2452820T3 (es) 2006-04-07 2014-04-02 Methylgene, Inc. Derivados de benzamida como inhibidores de histona desacetilasa
CN102643248A (zh) 2006-04-18 2012-08-22 日本化学医药株式会社 过氧化物酶体增殖剂激活受体δ的激活剂
DE102006024024A1 (de) * 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
CN101443330B (zh) 2006-06-13 2012-12-19 上海海和药物研究开发有限公司 杂环非核苷类化合物及其制备方法、药物组合物和作为抗病毒抑制剂的用途
CN100503571C (zh) 2006-07-12 2009-06-24 中国药科大学 四氢异喹啉类衍生物、其制备方法及其医药用途
AU2007277519B2 (en) 2006-07-27 2011-12-22 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
CA2662112A1 (en) 2006-09-05 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Imidazole derivatives and their use as cannabinoid type 2 (cb2) receptor modulators
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
CN101711154A (zh) 2007-02-26 2010-05-19 科森生物科学公司 氨基甲酸酯化合物
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
WO2010017545A2 (en) 2008-08-08 2010-02-11 Synta Pharamceuticals Corp. Triazole compounds that modulate hsp90 activity
AU2010271205A1 (en) 2009-07-09 2012-02-09 Moko Therapeutics Llc. Method of wound healing and scar modulation
WO2011069039A1 (en) 2009-12-04 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
US8513230B2 (en) 2010-03-05 2013-08-20 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US9303000B2 (en) 2011-01-17 2016-04-05 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
PL3333164T3 (pl) 2011-07-29 2023-12-18 Karyopharm Therapeutics Inc. Modulatory transportu jądrowego zawierające ugrupowanie hydrazydu i ich zastosowania
EA201490406A1 (ru) 2011-07-29 2014-07-30 Кариофарм Терапевтикс, Инк. Модуляторы ядерного транспорта и их применение
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
EP3404027B1 (en) 2012-05-09 2020-03-04 Biogen MA Inc. Nuclear transport modulators and uses thereof
US20160016916A1 (en) 2013-03-15 2016-01-21 Karyopharm Therapeutics Inc. Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
CN110183422B (zh) 2013-06-21 2023-07-14 卡尔约药物治疗公司 核转运调节剂及其用途
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11567063B2 (en) 2013-11-15 2023-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for assessing cell viability or predicting cell response to a treatment using cell movement
CA2954189A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
DK3180331T3 (da) 2014-08-15 2022-09-12 Karyopharm Therapeutics Inc Polymorfer af selinexor
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
US10709706B2 (en) 2015-12-31 2020-07-14 Karopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2017118940A1 (en) 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
JP6765198B2 (ja) 2016-03-10 2020-10-07 パナソニック株式会社 潜熱蓄熱材及びそれを用いる蓄熱システム
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
WO2018129227A1 (en) 2017-01-05 2018-07-12 Watson Laboratories Inc. Novel crystalline forms of selinexor and process for their preparation

Also Published As

Publication number Publication date
EP2736887A1 (en) 2014-06-04
CN103874690B (zh) 2016-07-06
EP2736887B1 (en) 2017-10-18
US11787771B2 (en) 2023-10-17
TWI574957B (zh) 2017-03-21
AU2012290454B2 (en) 2016-05-05
NL301119I2 (nl) 2021-09-15
US20200339521A1 (en) 2020-10-29
AU2016210682B2 (en) 2018-04-19
AU2018202441A1 (en) 2018-04-26
NZ719623A (en) 2017-12-22
AU2022203265A1 (en) 2022-06-02
PE20141170A1 (es) 2014-09-16
JP6005740B2 (ja) 2016-10-12
AU2020203121B2 (en) 2022-02-17
LUC00219I2 (no) 2022-10-07
CN110372672B (zh) 2023-09-29
CN110372672A (zh) 2019-10-25
JP2014521652A (ja) 2014-08-28
ES2655645T3 (es) 2018-02-21
US20140364408A1 (en) 2014-12-11
BR112014001934A2 (pt) 2017-02-21
WO2013019548A1 (en) 2013-02-07
NL301119I1 (no) 2021-08-04
JP2017036287A (ja) 2017-02-16
US9079865B2 (en) 2015-07-14
CL2014000225A1 (es) 2014-12-05
US9206158B2 (en) 2015-12-08
CA2842362A1 (en) 2013-02-07
JP6675431B2 (ja) 2020-04-01
SI2736887T1 (en) 2018-04-30
US10544108B2 (en) 2020-01-28
CN106083827A (zh) 2016-11-09
CO6960539A2 (es) 2014-05-30
CN110372673A (zh) 2019-10-25
EP3333164B1 (en) 2023-06-07
US20220073478A1 (en) 2022-03-10
KR20190045399A (ko) 2019-05-02
KR20230042129A (ko) 2023-03-27
CN117229268A (zh) 2023-12-15
KR20200088518A (ko) 2020-07-22
US20150274698A1 (en) 2015-10-01
AU2016210682A1 (en) 2016-08-18
NZ621904A (en) 2016-05-27
AU2020203121A1 (en) 2020-05-28
AU2012290454A1 (en) 2014-03-20
US20190330164A1 (en) 2019-10-31
DK2736887T3 (en) 2018-01-02
BR112014001934B1 (pt) 2020-12-15
HUS2100030I1 (hu) 2021-09-28
EP4234545A3 (en) 2023-09-06
CL2015001257A1 (es) 2015-09-21
US20140235653A1 (en) 2014-08-21
HRP20180014T1 (hr) 2018-04-20
EP3333164A1 (en) 2018-06-13
LTPA2021007I1 (no) 2021-08-25
EP4234545A2 (en) 2023-08-30
DK3333164T3 (da) 2023-09-18
UA115532C2 (uk) 2017-11-27
KR20210083380A (ko) 2021-07-06
JP2018111713A (ja) 2018-07-19
MX2014001181A (es) 2014-07-14
CY1119783T1 (el) 2018-06-27
PT2736887T (pt) 2018-01-15
LT2736887T (lt) 2018-02-12
CN106083827B (zh) 2019-09-17
KR20140066179A (ko) 2014-05-30
PL2736887T3 (pl) 2018-03-30
TW201311666A (zh) 2013-03-16
CN110372673B (zh) 2023-10-03
ME02936B (me) 2018-04-20
MX349712B (es) 2017-08-09
KR102022716B1 (ko) 2019-09-18
US9714226B2 (en) 2017-07-25
US11034660B2 (en) 2021-06-15
AR087342A1 (es) 2014-03-19
US10173987B2 (en) 2019-01-08
US8999996B2 (en) 2015-04-07
CN103874690A (zh) 2014-06-18
LTC2736887I2 (no) 2022-10-25
ZA201401223B (en) 2022-03-30
JP6309057B2 (ja) 2018-04-11
PL3333164T3 (pl) 2023-12-18
FR21C1042I1 (no) 2021-11-19
AU2018202441B2 (en) 2020-02-13
HUE036058T2 (hu) 2018-06-28
HK1256745A1 (zh) 2019-10-04
GEP201706616B (en) 2017-02-10
CA2842362C (en) 2020-06-16
US20160304472A1 (en) 2016-10-20
KR102136768B1 (ko) 2020-07-23
ES2954991T3 (es) 2023-11-28
FR21C1042I2 (fr) 2022-09-02
RS56823B1 (sr) 2018-04-30
US20180127384A1 (en) 2018-05-10
HK1198477A1 (en) 2015-05-08
EA201490407A1 (ru) 2014-05-30

Similar Documents

Publication Publication Date Title
NO2021033I1 (no) Selineksor eller et farmasøytisk akseptabelt salt derav
NO2021034I1 (no) pemigatinib or a pharmaceutically acceptable salt thereof
NO2017057I1 (no) pibrentasvir eller et farmasøytisk akseptabelt salt derav
NO2020047I1 (no) Remdesivir eller et farmasøytisk akseptabelt salt eller ester derav
NO2022031I1 (no) Voxelotor or a tautomer or pharmaceutically acceptable salt thereof
NO2021041I1 (no) remimazolam or a pharmaceutically acceptable salt thereof
NO2022044I1 (no) daridorexant eller et farmasøytisk akseptabelt salt derav, spesielt daridorexant hydroklorid
FIC20230028I1 (fi) Deukravasitinibi tai sen framaseuttisesti hyväksyttävä suola
NO2023046I1 (no) Futibatinib eller et salt derav
NO2022010I1 (no) ripretinib, or a pharmaceutically acceptable salt thereof
FIC20240012I1 (fi) Omaveloksoloni tai sen farmaseuttisesti hyväksyttävä suola
NO2019019I1 (no) Doravirin eller et farmasøytisk akseptabelt salt derav
NO2023040I1 (no) Atogepant or a pharmaceutically acceptable salt thereof
LUC00083I2 (en) Bictegravir or a pharmaceutically acceptable salt thereof, in particular bictegravir sodium
NO2019008I1 (no) Allopurinol/lesinurad eller et farmasøytisk aksepterbart salt eller salter derav
CO6890099A2 (es) Nuevos derivados dihidroquinolina-2-ona
DK2526989T3 (da) System omfattende en forstøver
BR112014007261A2 (pt) dispositivo de recolha de encomendas farmacêuticas
BR112014013739A2 (pt) plataforma estrutural
DK2734499T3 (da) Merocyanine derivatives
BR112014000879A2 (pt) deflegmador
NO2022002I1 (no) tasipimidine optionally in the form of a pharmaceutically acceptable salt thereof, in particular tasipimidine sulfate
FI20115270A (fi) Lentolaite
FR2982524B1 (fr) Structure multicouche
BR112014005756A2 (pt) vacina